Partnership Overview
Brenntag Specialties has entered into a sole distribution partnership with Seqens for the distribution of non-GMP pharmaceutical intermediates in Europe. This agreement covers more than 30 intermediates, marking a significant step in optimizing Brenntag’s portfolio for API synthesis.
Quality and Flexibility
The pharmaceutical industry relies on high-quality products at every stage of chemical synthesis. This partnership allows Brenntag to offer high-quality intermediates from Seqens, a well-known global CDMO and ingredient manufacturer, to a broad customer base. Seqens provides a reliable and competitive solution for non-GMP intermediate needs, optimizing lead times and flexibility.
Supply Chain and Market Impact
Brenntag customers will benefit from enhanced regulatory depth, quality, flexibility, and a secure supply chain with production based in Europe. The partnership aims to improve the availability of non-GMP pharmaceutical intermediates and expand coverage in Europe through Brenntag’s logistics and commercial expertise.
Strategic Goals
This collaboration is part of Seqens' strategy to stay close to customers and strengthen its presence in the European market. It enables quick responses to market demands while maintaining high standards of quality and safety.
